Stockreport

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; in [Read more]